GSK3528869A (GSK)

GSK3528869A is an investigational therapeutic, adjuvanted recombinant protein vaccine developed by GSK for the treatment of chronic hepatitis B (CHB). It is designed to stimulate a robust immune response against the hepatitis B virus (HBV) by targeting the HBV surface antigen (HBsAg). The vaccine is typically evaluated as part of a prime-boost regimen, often in combination with GSK's HBV viral vector vaccines or antisense oligonucleotides like bepirovirsen. The goal of these combinations is to achieve a functional cure for CHB by reducing HBsAg levels and restoring the host's immune control over the virus. It has been studied in Phase I/II clinical trials, including sequential or co-administration schedules in adults with CHB who are well-controlled on nucleos(t)ide analogue therapy.

Other names

TH HBV adjuvanted recombinant protein vaccineGSK HBV protein vaccine